Boston Partners decreased its holdings in Biogen Inc. (NASDAQ:BIIB - Free Report) by 28.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 901,213 shares of the biotechnology company's stock after selling 362,216 shares during the quarter. Boston Partners owned about 0.61% of Biogen worth $203,556,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Independent Advisor Alliance lifted its position in Biogen by 10.1% in the third quarter. Independent Advisor Alliance now owns 1,388 shares of the biotechnology company's stock valued at $341,000 after buying an additional 127 shares during the last quarter. Meeder Asset Management Inc. lifted its holdings in shares of Biogen by 4,819.4% in the 3rd quarter. Meeder Asset Management Inc. now owns 1,771 shares of the biotechnology company's stock worth $400,000 after acquiring an additional 1,735 shares during the last quarter. Composition Wealth LLC boosted its position in shares of Biogen by 1,465.8% during the 3rd quarter. Composition Wealth LLC now owns 22,250 shares of the biotechnology company's stock worth $5,026,000 after purchasing an additional 20,829 shares during the period. Voya Investment Management LLC increased its holdings in Biogen by 199.4% in the 3rd quarter. Voya Investment Management LLC now owns 738,972 shares of the biotechnology company's stock valued at $166,919,000 after purchasing an additional 492,190 shares during the last quarter. Finally, Bogart Wealth LLC increased its holdings in Biogen by 1,367.7% in the 3rd quarter. Bogart Wealth LLC now owns 3,229 shares of the biotechnology company's stock valued at $729,000 after purchasing an additional 3,009 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.
Key Stories Impacting Biogen
Here are a few of the latest stories about BIIB:
- Positive Sentiment: New three-year real-world LEQEMBI findings showed a 76% lower rate of progression to moderate or severe Alzheimer’s dementia versus a matched natural-history cohort. If confirmed, the results could support the drug’s commercial opportunity. Three-year real-world LEQEMBI data
- Positive Sentiment: Biogen also reported encouraging two-year Phase 2 results for diranersen in early Alzheimer’s, adding to its longer-term Alzheimer’s pipeline prospects. Diranersen two-year data
- Negative Sentiment: A recent analyst commentary downgraded Biogen, arguing that M&A-driven growth and Alzheimer’s progress may already be priced in. Another report described analyst views as mixed, potentially limiting enthusiasm despite the favorable data. Biogen rating downgrade commentary
Biogen Stock Down 1.7%
Shares of NASDAQ:BIIB opened at $247.13 on Friday. The firm has a 50 day simple moving average of $236.18 and a 200-day simple moving average of $206.49. Biogen Inc. has a twelve month low of $160.36 and a twelve month high of $261.00. The company has a current ratio of 1.95, a quick ratio of 1.37 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $36.53 billion, a PE ratio of 21.34, a P/E/G ratio of 2.85 and a beta of 0.10.
Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, beating the consensus estimate of $1.99 by $0.63. The firm had revenue of $2.80 billion during the quarter, compared to the consensus estimate of $2.63 billion. Biogen had a net margin of 3.37% and a return on equity of 9.38%. Biogen's revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $4.81 EPS. On average, equities analysts predict that Biogen Inc. will post 12.46 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on the company. Weiss Ratings downgraded Biogen from a "hold (c)" rating to a "hold (c-)" rating in a report on Thursday, October 29th. Wedbush lifted their target price on Biogen from $212.00 to $225.00 and gave the company a "neutral" rating in a research report on Thursday, October 29th. UBS Group boosted their price target on shares of Biogen from $270.00 to $300.00 and gave the stock a "buy" rating in a research note on Thursday, October 29th. Wells Fargo & Company increased their price target on shares of Biogen from $250.00 to $310.00 and gave the stock an "overweight" rating in a research report on Tuesday, October 20th. Finally, Robert W. Baird raised their price objective on shares of Biogen from $250.00 to $290.00 and gave the company an "outperform" rating in a research note on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $254.41.
Read Our Latest Stock Report on BIIB
Biogen Profile
(
Free Report)
Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer's disease, spinal muscular atrophy and Friedreich's ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich's ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer's disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.
Further Reading
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Biogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.
While Biogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.